上海复宏汉霖生物技术股份有限公司 Henlius Mediaroom

Henlius' Serplulimab (anti-PD-1 mAb) Granted Breakthrough Therapy Designation by China NMPA for Neo-/Adjuvant Treatment for Gastric Cancer

* The first CDE-designated Breakthrough Therapy for perioperative gastric cancer, promising accel...

2025-11-20 18:52 1163

Henlius and Organon Announce US FDA Approval of POHERDY® (pertuzumab-dpzb), the First PERJETA (pertuzumab) Biosimilar in the US

SHANGHAI and JERSEY CITY, N.J., Nov. 17, 2025 /PRNewswire/ -- Shanghai Henlius Biotech, Inc. (2696....

2025-11-17 22:06 1124

Phase 3 Clinical Trial of HANSIZHUANG Plus Chemotherapy Meets Primary Endpoint in Neoadjuvant/Adjuvant Gastric Cancer, Greenlighting Early NDA Submission

* The phase 3 clinical trial of HANSIZHUANG for perioperative gastric cancer treatment met its EF...

2025-10-09 20:50 1443

European Commission (EC) Approves Henlius and Organon's BILDYOS® (denosumab) and BILPREVDA® (denosumab), Biosimilars to PROLIA (denosumab) and XGEVA (denosumab), Respectively

SHANGHAI and JERSEY CITY, N.J., Sept. 19, 2025 /PRNewswire/ -- Shanghai Henlius Biotech, Inc. (2696...

2025-09-19 19:59 2572

FUTUONING Sets Sail Commercially with First Prescriptions Across China

SHANGHAI, Sept. 5, 2025 /PRNewswire/ -- These days, the first prescriptions of FUTUONING (fovinacic...

2025-09-05 18:12 1743

US Food and Drug Administration (FDA) Approves Henlius and Organon's BILDYOS® (denosumab-nxxp) and BILPREVDA® (denosumab-nxxp), Biosimilars to PROLIA (denosumab) and XGEVA (denosumab), Respectively

SHANGHAI and JERSEY CITY, N.J., Sept. 2, 2025 /PRNewswire/ -- Shanghai Henlius Biotech, Inc. (2696....

2025-09-02 21:10 2108

Henlius Keeps Steady Growth in H1 2025: Overseas Product Profits Soar 200%+, Innovation Fuels Global Reach

SHANGHAI, Aug. 25, 2025 /PRNewswire/ -- Henlius (2696.HK) announced its 2025 interim results. In th...

2025-08-25 21:18 2774

Henlius Enters into License Agreement with Sandoz for Proposed Ipilimumab Biosimilar

* Partnership covers North America, Europe, Japan, and Australia to accelerate global access of H...

2025-04-29 23:39 2854

Henlius Enters into License Agreement with Sandoz for Proposed Ipilimumab Biosimilar

* Partnership covers North America, Europe, Japan, and Australia to accelerate global access of H...

2025-04-29 23:38 2432

Henlius 2025 Global R&D Day: Harnessing the Power of Innovation to Propel Global Strategy to New Heights

SHANGHAI, April 17, 2025 /PRNewswire/ -- Henlius (2696.HK) held its 2025 Global R&D Day themed "Col...

2025-04-17 16:07 4344

Henlius 2025 Global R&D Day: Harnessing the Power of Innovation to Propel Global Strategy to New Heights

SHANGHAI, April 16, 2025 /PRNewswire/ -- Henlius (2696.HK) held its 2025 Global R&D Day under the t...

2025-04-16 23:30 3048

Putting Patients First, Co-Creating a Bright Future for Human Health: Henlius Releases 2024 ESG Report

SHANGHAI, April 16, 2025 /PRNewswire/ -- On April 15, 2025, Henlius (2696.HK) released the "2024 En...

2025-04-16 23:22 2614

Henlius 2024 Annual Results: Steady Revenue Growth with a Net Profit of RMB820.5 million, Up by 50.3% YoY

SHANGHAI, March 24, 2025 /PRNewswire/ -- Henlius (2696.HK) announced its 2024 annual results. Durin...

2025-03-24 23:09 3075

Henlius 2024 Annual Results: Steady Revenue Growth with a Net Profit of RMB820.5 million, Up by 50.3% YoY

SHANGHAI, March 24, 2025 /PRNewswire/ -- Henlius (2696.HK) announced its 2024 annual results. Durin...

2025-03-24 22:54 3412

Henlius Receives Orphan Drug Designation for Innovative Anti-HER2 mAb HLX22 in the U.S. for Gastric Cancer

SHANGHAI, March 19, 2025 /PRNewswire/ -- Shanghai Henlius Biotech, Inc. (2696.HK) announced that th...

2025-03-19 23:17 2236

Henlius Receives Orphan Drug Designation for Innovative Anti-HER2 mAb HLX22 in the U.S. for Gastric Cancer

SHANGHAI, March 19, 2025 /PRNewswire/ -- Shanghai Henlius Biotech, Inc. (2696.HK) announced that th...

2025-03-19 21:00 2099

Henlius and Dr. Reddy's Ink Licensing Deal for HLX15 (investigational daratumumab biosimilar) Expansion in Europe and the U.S.

SHANGHAI, Feb. 6, 2025 /PRNewswire/ -- Shanghai Henlius Biotech, Inc. (2696.HK) today announced it ...

2025-02-06 19:40 3531

Serplulimab Approved in the EU for First-Line Treatment of Extensive-Stage Small Cell Lung Cancer (ES-SCLC)

* Serplulimab is the world's first anti-PD-1 monoclonal antibody (mAb) approved for first-line tr...

2025-02-05 22:05 3571

Henlius and SVAX Forge Strategic Partnership in the MENAT Market

SHANGHAI, Nov. 8, 2024 /PRNewswire/ -- On the morning of November 7, at the 7th China International...

2024-11-09 00:35 5580

Henlius and SVAX Forge Strategic Partnership in the MENAT Market

Henlius Receives Positive CHMP Opinion for HANSIZHUANG as First-Line Treatment for Extensive-Stage Small Cell Lung Cancer

* HANSIZHUANG (serplulimab) is the world's first anti-PD-1 mAb for first-line treatment of ES- SC...

2024-09-21 13:42 5524

Latest News